文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

MIPSS70+ v2.0可预测接受Flu/Mel预处理方案异基因造血干细胞移植的骨髓纤维化患者的长期生存

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
PubMed 文献 · Blood Adv · 2019-01-01

该单中心回顾性研究纳入110例接受氟达拉滨/美法仑(Flu/Mel)预处理异基因造血干细胞移植的骨髓纤维化患者,中位随访63.7个月,5年总生存率为65%,非复发死亡率为17%。CBL突变与较低总生存(HR 2.64,P=0.032)和较高非复发死亡(HR 3.68,P=0.004)显著相关。按MIPSS70+ v2.0分类,中危较高危总生存更好(HR 0.291),极高危较高危总生存更低(HR 5.05,P≤0.001)。

要点

  • CBL突变与移植后较低OS(HR 2.64,P=0.032)和较高NRM(HR 3.68,P=0.004)显著相关。
  • CALR、ASXL1和IDH突变对移植结局无显著影响。
  • MIPSS70+ v2.0极高危较高危OS更低(HR 5.05,P≤0.001),中危较高危OS更好(HR 0.291)。

核心结论

  • 修订的细胞遗传学改变和MIPSS70+ v2.0评分可预测移植结局,从而能更好地帮助医生和患者做出关于异基因造血干细胞移植的决策。

研究设计与样本

  • 单中心回顾性研究,纳入110例连续接受氟达拉滨/美法仑(Flu/Mel)预处理异基因造血干细胞移植的骨髓纤维化患者,基于72基因二代测序面板和MIPSS70+ v2.0评估分子标志物对结局的影响。

主要发现

  • 中位随访63.7个月,5年总生存率为65%,非复发死亡率为17%。
  • JAK2 V617F和ASXL1突变是最常见的突变。
  • 单变量分析中,较高的动态国际预后评分系统评分、无关供者类型和极高危细胞遗传学与较低总生存显著相关。
  • 仅CBL突变与移植后较低总生存(HR 2.64,P=0.032)和较高非复发死亡(HR 3.68,P=0.004)显著相关,CALR、ASXL1和IDH突变对移植结局无影响。
  • 按MIPSS70分类,高危患者较中危患者总生存更差(HR 0.49,P=0.039);按MIPSS70+ v2.0分类,中危较高危总生存更好(HR 0.291),极高危较高危总生存更低(HR 5.05,P≤0.001)。

临床怎么用

  • 作者认为修订的细胞遗传学改变和MIPSS70+ v2.0评分可预测移植结局,能更好地帮助医生和患者做出关于异基因造血干细胞移植的决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for myelofibrosis (MF), data are limited on how molecular markers predict transplantation outcomes. We retrospectively evaluated transplantation outcomes of 110 consecutive MF patients who underwent allo-HCT with a fludarabine/melphalan (Flu/Mel) conditioning regimen at our center and assessed the impact of molecular markers on outcomes based on a 72-gene next-generation sequencing panel and Mutation-Enhanced International Prognostic Scoring System 70+ v2.0 (MIPSS70+ v2.0). With a median follow-up of 63.7 months, the 5-year overall survival (OS) rate was 65% and the nonrelapse mortality (NRM) rate was 17%. In mutational analysis, JAK2 V617F and ASXL1 mutations were the most common. By univariable analysis, higher Dynamic International Prognostic Scoring System scores, unrelated donor type, and very-high-risk cytogenetics were significantly associated with lower OS. Only CBL mutations were significantly associated with lower OS (hazard ratio [HR], 2.64; P = .032) and increased NRM (HR, 3.68; P = .004) after allo-HCT, but CALR, ASXL1, and IDH mutations did not have an impact on transplantation outcomes. Patient classification per MIPSS70 showed worse OS for high-risk (HR, 0.49; P = .039) compared with intermediate-risk patients. Classification per MIPSS70+ v2.0 demonstrated better OS when intermediate-risk patients were compared with high-risk patients (HR, 0.291) and much lower OS when very-high-risk patients were compared with high-risk patients (HR, 5.05; P ≤ .001). In summary, we present one of the largest single-center experiences of Flu/Mel-based allo-HCT, demonstrating that revised cytogenetic changes and MIPSS70+ v2.0 score predict transplantation outcomes, and thus can better inform physicians and patients in making decisions about allo-HCT.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Ali H, Aldoss I, Yang D, et al. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Blood Adv. 2019. PMID: 30622146. doi:10.1182/bloodadvances.2018026658

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。